Trials / Completed
CompletedNCT05347576
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 31 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- All
- Age
- 19 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed Conditions
Detailed description
A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-393(2) in healthy volunteers under fed conditions
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CKD-393(2) | QD, PO |
| DRUG | CKD-501, D759, D150, D029 | QD, PO |
Timeline
- Start date
- 2022-04-21
- Primary completion
- 2022-05-02
- Completion
- 2022-05-09
- First posted
- 2022-04-26
- Last updated
- 2022-06-30
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05347576. Inclusion in this directory is not an endorsement.